Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), saw four insiders lower their exposure to the company. William P. Forbes, the EVP of Research & Development & the company’s CDO, sold 1,971 shares of common stock at an average of $123.35 per share; EVP of Finance & CFO Adam C. Derbyshire disposed of 2,458 shares at an average of $123.32 per share; Executive VP Rick D. Scruggs lowered his position in the company by 1,243 shares at an average of $123.35 per share; while the company’s President & CEO Carolyn J. Logan decreased her holdings by 8,253 shares at an average of $123.35 per share.
Following these transactions, Forbes now owns 99,411 shares directly; Derbyshire directly has 197,700 shares; Scruggs directly holds 68,811 shares; while Logan has 613,154.2 shares directly, and 400,000 shares indirectly in Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), the $8.85 billion market cap pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders.
As well, Baker Bros. Advisors, the hedge fund managed by Julian Baker And Felix Baker holds 219,440,000 shares in the company, worth approximately $4.2 million.
Disclosure: The author, Daniel Forstein, holds no positions in any stocks mentioned.
